BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $8,366,726 | +41.1% | 317,282 | -8.0% | 0.00% | +50.0% |
Q2 2023 | $5,928,737 | +123.5% | 344,694 | +115.4% | 0.00% | +100.0% |
Q1 2023 | $2,652,999 | +544.1% | 160,012 | +196.0% | 0.00% | – |
Q4 2022 | $411,921 | +104.9% | 54,058 | +167.9% | 0.00% | – |
Q3 2022 | $201,000 | -72.5% | 20,175 | -75.0% | 0.00% | – |
Q2 2022 | $731,000 | -76.0% | 80,548 | -73.2% | 0.00% | -100.0% |
Q1 2022 | $3,045,000 | -83.9% | 300,092 | -73.5% | 0.00% | -83.3% |
Q4 2021 | $18,884,000 | +159.7% | 1,132,137 | +629.8% | 0.01% | +100.0% |
Q3 2021 | $7,271,000 | +0.7% | 155,140 | +31.0% | 0.00% | +50.0% |
Q2 2021 | $7,221,000 | +39.5% | 118,462 | +41.0% | 0.00% | -33.3% |
Q1 2021 | $5,175,000 | +5.9% | 84,012 | +22.3% | 0.00% | +50.0% |
Q4 2020 | $4,885,000 | +334.2% | 68,690 | +129.1% | 0.00% | +100.0% |
Q3 2020 | $1,125,000 | -23.5% | 29,983 | -33.5% | 0.00% | 0.0% |
Q2 2020 | $1,470,000 | – | 45,077 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |